Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 11/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 10/20 | 0.49 |
| ▸ | PPARA | Q07869 | 6/20 | 0.49 |
| ▸ | KIF11 | P52732 | 4/20 | 0.47 |
| ▸ | PTGES | O14684 | 9/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31676108 | 0.95 | HSD17B10 (0.47) | HSD17B10PPARGALOX5PPARAKIF11 | |
| SCHEMBL1929859 | 0.85 | KIF11 (0.52) | PPARGALOX5PPARAKIF11PTGES | |
| SCHEMBL4454777 | 0.83 | POLB (0.49) | KIF11POLB | |
| SCHEMBL4838957 | 0.79 | KIF11 (0.44) | PPARGPPARAKIF11 | |
| SCHEMBL4839082 | 0.78 | KIF11 (0.43) | KIF11EPHX1 | |
| SCHEMBL4158244 | 0.77 | KDM4E (0.50) | KIF11POLBKMT2AL3MBTL1 | |
| SCHEMBL8442261 | 0.76 | MMP2 (0.46) | L3MBTL1 | |
| SCHEMBL5080497 | 0.76 | PPARG (0.72) | HSD17B10PPARGALOX5PPARAPTGES | |
| SCHEMBL4839273 | 0.76 | CYP1A2 (0.48) | HSD17B10PPARGPPARAKIF11 | |
| SCHEMBL4831433 | 0.76 | CYP1A2 (0.48) | HSD17B10PPARGPPARAKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198218-B2 | Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2012-06-12 | — | — | US | disclosed |
| EP-2459171-A1 | LONG ACTING INSULIN COMPOSITION | Sanofi-Aventis Deutschland GmbH (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | ASCENDIS PHARMA AS (DK) | 2012-03-08 | — | — | US | disclosed |
| EP-2403537-A1 | INTERFERON ALPHA CARRIER PRODRUGS | Ascendis Pharma A/S (DK) | 2012-01-11 | — | — | EP | disclosed |
| WO-2011012723-A1 | INJECTABLE SUSTAINED RELEASE COMPOSITIONS COMPRISING A PRAMIPEXOLE PRODRUG | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012719-A1 | LONG ACTING INSULIN COMPOSITION | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| WO-2010100220-A1 | INTERFERON ALPHA CARRIER PRODRUGS | ASCENDIS PHARMA AS (DK) | 2010-09-10 | — | — | WO | disclosed |
| US-20100022499-A1 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM | 2010-01-28 | — | — | US | disclosed |
| US-7365091-B2 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2008-04-29 | — | — | US | disclosed |
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2006-12-21 | — | — | US | disclosed |
| US-7105539-B2 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-09-12 | — | — | US | disclosed |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-06-22 | — | — | US | disclosed |
| EP-1461324-A4 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS | YISSUM RES DEV CO (IL) | 2006-02-01 | — | — | EP | disclosed |
| US-20050266496-A1 | Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-12-01 | — | — | US | disclosed |
| EP-1572645-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | Enobia Pharma Inc. (CA) | 2005-09-14 | — | — | EP | disclosed |
| EP-1461324-A2 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS | Yissum Research Development Company of the Hebrew University of Jerusalem (IL) | 2004-09-29 | — | — | EP | disclosed |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | BIOMEP INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004050620-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | ENOBIA PHARMA (CA) | 2004-06-17 | — | — | WO | disclosed |
| US-20030144260-A1 | Heterocyclic compounds, method of developing new drug leads and combinatorial libraries used in such method | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-07-31 | — | — | US | disclosed |
| WO-2003059876-A2 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | GLS, SUCNR1, PGD | HSD17B10 322/4885PPARG 1182/4885ALOX5 1439/4885 |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, PGD | HSD17B10 303/4885PPARG 1228/4885ALOX5 1437/4885 |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, GCDH | HSD17B10 279/4885PPARG 1112/4885ALOX5 1336/4885 |
| US-20030144260-A1 | Heterocyclic compounds, method of developing new drug leads and combinatorial libraries used in such method | AADAC, ABCG2, HDAC3 | HSD17B10 153/4885PPARG 2117/4885ALOX5 3729/4885 |
| US-20100022499-A1 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS | AADAC, ABCG2, RICTOR | HSD17B10 486/4885PPARG 1378/4885ALOX5 3752/4885 |
| US-20050266496-A1 | Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads | AADAC, ABCG2, RICTOR | HSD17B10 486/4885PPARG 1378/4885ALOX5 3752/4885 |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | IFNG, IFNAR1, IRF3 | HSD17B10 1124/4885PPARG 1605/4885ALOX5 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.